# Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells

> **NCT03980249** · EARLY_PHASE1 · WITHDRAWN · sponsor: **West Virginia University**

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT03980249
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09
- **Primary completion:** 2021-12
- **Final completion:** 2022-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding
- **Last updated:** 2021-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980249, "Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03980249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*